Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX

Eventide Asset Management LLC raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 37.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,859,095 shares of the biopharmaceutical company’s stock after purchasing an additional 502,909 shares during the period. Eventide Asset Management LLC owned 2.80% of Celldex Therapeutics worth $48,096,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Handelsbanken Fonder AB boosted its position in shares of Celldex Therapeutics by 2.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 500 shares in the last quarter. Russell Investments Group Ltd. increased its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 680 shares in the last quarter. DNB Asset Management AS raised its stake in Celldex Therapeutics by 7.7% during the 3rd quarter. DNB Asset Management AS now owns 13,251 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 951 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new position in Celldex Therapeutics during the 3rd quarter worth approximately $26,000.

Analyst Upgrades and Downgrades

CLDX has been the subject of a number of research reports. The Goldman Sachs Group raised their price objective on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. Barclays increased their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $29.51 on Friday. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $31.99. The company has a market cap of $1.96 billion, a PE ratio of -7.59 and a beta of 1.17. The firm has a 50-day moving average of $26.34 and a 200-day moving average of $25.98.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.